Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

JCR-Journal of Clinical Rheumatology, published by Lippincott Williams & Wilkins, is a premier outlet dedicated to the field of rheumatology, recognized for its contributions and relevance among medical journals. Boasting an impact factor reflective of its vital role in disseminating innovative research, it currently holds a Q2 category ranking in Medicine (miscellaneous) and a Q3 ranking in Rheumatology as of 2023. With its convergence years spanning from 1995 to 2024, the journal aims to foster the advancement of knowledge in clinical practices, therapeutic advances, and patient management strategies concerning rheumatic diseases. Researchers, professionals, and students can access a wealth of benchmark studies and peer-reviewed articles, enhancing their understanding and collaboration within this dynamic field. By bridging clinical insights with rigorous research, the JCR-Journal of Clinical Rheumatology remains an important resource for advancing the understanding of rheumatologic disorders and improving patient care.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Revista Cubana de Reumatologia is a prominent open-access journal published by the SOC CUBANA REUMATOLOGIA, dedicated to advancing knowledge in the field of rheumatology since its inception in 1998. With an ISSN of 1606-5581 and an E-ISSN of 1817-5996, this journal aims to disseminate high-quality research that addresses various aspects of rheumatic diseases, their diagnosis, treatment, and management. Located in Havana, Cuba, the journal serves as a vital platform for both local and international researchers, professionals, and students interested in the latest developments within the specialty. By embracing an open-access policy, the journal ensures that groundbreaking studies are freely available to a global audience, fostering collaboration and innovation in rheumatological research. As the field continues to evolve, Revista Cubana de Reumatologia remains committed to addressing the emerging challenges and trends, making it an essential resource for practitioners and scholars alike.

SEMINARS IN ARTHRITIS AND RHEUMATISM, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of rheumatology and pain medicine. With an impressive impact factor and recognized as a Q1 journal in both its categories, it ranks #8 in Anesthesiology and Pain Medicine and #11 in Rheumatology based on the latest Scopus data, placing it within the top echelons of academic research. Established in 1971, this esteemed publication offers a comprehensive platform for researchers and practitioners to disseminate and engage with cutting-edge studies that advance the understanding and treatment of arthritis and related conditions. With its robust editorial process and focus on high-quality, peer-reviewed articles, the journal not only contributes to scientific knowledge but also serves as an essential resource for professionals and students seeking contemporary insights into effective management strategies and emerging therapies in the rheumatologic field. Although it does not offer open access, its subscription model ensures a wide distribution among academic and clinical institutions, reinforcing its significance in the research community.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

JOURNAL OF RHEUMATOLOGY, published by the J Rheumatol Publ Co, stands as a distinguished platform within the fields of rheumatology and immunology since its inception in 1974. With an impressive impact evidenced by its 2023 rankings—Q1 in Rheumatology and Q2 in both Immunology and Allergy—the journal has secured its position as a vital resource for researchers and practitioners alike. The journal is dedicated to advancing clinical and experimental knowledge in the pathogenesis, diagnosis, and management of rheumatic diseases, providing a rich repository of peer-reviewed articles that drive innovation in treatment protocols and patient care. Although it operates under a subscription model, the journal remains accessible to a broad audience committed to advancing their understanding of these critical areas. Located in Toronto, Canada, it continues to attract contributions from leading experts globally, making it an essential read for anyone keen on staying at the forefront of rheumatological research and practice.

Dermatologie, published by SPRINGER HEIDELBERG, is a prominent journal dedicated to the advancing field of dermatology. With its ISSN 2731-7005 and E-ISSN 2731-7013, this journal has established itself as a valuable resource for researchers, professionals, and students alike. Originating in Germany, the journal focuses on disseminating innovative research from 2022 to 2024, contributing significantly to the understanding of skin health and disease management. Despite its current ranking within the Q3 category in dermatology and a Scopus rank of #88/142, it provides critical insights and advances in clinical practice, epidemiology, and therapeutic modalities. With an emphasis on open discourse, it seeks to foster collaboration among healthcare professionals and researchers, thereby enhancing the quality and accessibility of dermatological research. Engage with Dermatologie to stay at the forefront of the latest advancements in skin-related health issues.